Unknown PHASE1/PHASE2 INTERVENTIONAL 1-arm NCT03165591

Open Label Immunotherapy Trial of Inoperable Pancreatic Cancer (V3-P)

Open Label Phase II Immunotherapy Trial of Inoperable Pancreatic Cancer

Sponsor: Immunitor LLC

Conditions Pancreatic Cancer Non-resectable

Interventions V3-P

Updated 8 times since 2017 Last updated: Aug 29, 2019 Started: May 1, 2017 Primary completion: Feb 28, 2020 Completion: Dec 31, 2020

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1/PHASE2 trial investigates Pancreatic Cancer Non-resectable and is currently ongoing. Immunitor LLC leads this study, which shows 8 recorded versions since 2017 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

8 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE1/PHASE2
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE1/PHASE2

Status: Unknown Status → Unknown · Phase: PHASE1_PHASE2 → PHASE1/PHASE2
Oct 2021 — Jul 2024 [monthly]

Unknown Status PHASE1_PHASE2

Status: Recruiting → Unknown Status
Jan 2021 — Oct 2021 [monthly]

Recruiting PHASE1_PHASE2
Sep 2019 — Jan 2021 [monthly]

Recruiting PHASE1_PHASE2

▶ Show 3 earlier versions

Sep 2018 — Sep 2019 [monthly]

Recruiting PHASE1_PHASE2
Jun 2018 — Sep 2018 [monthly]

Recruiting PHASE1_PHASE2
Jun 2017 — Jun 2018 [monthly]

Recruiting PHASE1_PHASE2

First recorded

May 2017

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Immunitor LLC

Data source: Immunitor LLC

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Ulaanbaatar, Mongolia